Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286

Journal of Infectious Diseases

Volumn 211, Issue 5, 2015, Pages 780-790

  Tenorio, Allan R ^a,k   Chan, Ellen S ^d   Bosch, Ronald J ^d   Macatangay, Bernard J C ^e   Read, Sarah W ^g   Yesmin, Suria ^h   Taiwo, Babafemi ^c   Margolis, David M ⁱ   Jacobson, Jeffrey M ^f   Landay, Alan L ^b   Wilson, Cara C ^j  

^a Department of Medicine ^*  (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f DREXEL UNIVERSITY   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF COLORADO   (United States)

^k GLAXOSMITHKLINE   (United States)

more..

Author keywords

HIV; Immune activation; Immune nonresponders to ART; Inflammation; Microbial translocation; Rifaximin

Indexed keywords

C REACTIVE PROTEIN; CD146 ANTIGEN; CD163 ANTIGEN; CD38 ANTIGEN; D DIMER; INTERLEUKIN 6; RIFAXIMIN; TRIACYLGLYCEROL LIPASE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; ANTIINFECTIVE AGENT; CD14 ANTIGEN; LIPOPOLYSACCHARIDE; RIFAMYCIN;

ADULT; ANOREXIA; ANTIVIRAL THERAPY; BACTERIAL TRANSLOCATION; BLOOD CLOTTING; CD8+ T LYMPHOCYTE; CONFERENCE PAPER; CONSTIPATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLATULENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH PAIN; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIREMIA; ADOLESCENT; AGED; BLOOD; CLINICAL TRIAL; COMPLICATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTIGENS, CD14; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BACTERIAL TRANSLOCATION; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RIFAMYCINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84939509426     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu515     Document Type: Conference Paper

References (35)

1. Liu Z, Cumberland WG, Hultin LE, Kaplan AH, Detels R, Giorgi JV. CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:332-40.
2. + T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003;187:1534-43.
3. Anthony KB, Yoder C, Metcalf JA, et al. Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J Acquir Immune Defic Syndr 2003;33:125-33.
4. + T cells. J Infect Dis 2009;200:1212-5.
5. Gandhi RT, Spritzler J, Chan E, et al. Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr 2006;42:426-34.
6. Lederman MM, Calabrese L, Funderburg NT, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis 2011;204:1217-26.
7. Chene G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003;362:679-86.
8. Van Lelyveld SF, Gras L, Kesselring A, et al. Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort. AIDS 2012;26:465-74.
9. + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004;200:749-59.
10. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365-71.
11. Chun TW, Nickle DC, Justement JS, et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008;197:714-20.
12. + T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003;77:11708-17.
13. Jiang W, Lederman MM, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009;199:1177-85.
14. Pedersen KK, Pedersen M, Troseid M, et al. Microbial translocation in HIV infection is associated with dyslipidemia, insulin resistance, and risk of myocardial infarction. J Acquir Immune Defic Syndr 2013;64:425-33.
15. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011;203:780-90.
16. Vlachogiannakos J, Saveriadis AS, Viazis N, et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther 2009;29:992-9.
17. Brumback LC, Pepe MS, Alonzo TA. Using the ROC curve for gauging treatment effect in clinical trials. Stat Med 2006;25:575-90.
18. De Long ER, De Long DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
19. Kothary V, Scherl EJ, Bosworth B, et al. Rifaximin resistance in Escher-ichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naph-thylamide-inhibitable efflux pumps. Antimicrob Agents Chemother 2013;57:811-7.
20. Bajaj JS, Heuman DM, Sanyal AJ, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopa-thy. PLoS One 2013;8:e60042.
21. Mutlu EA, Keshavarzian A, Losurdo J, et al. A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. PLoS Pathog 2014;10:e1003829.
22. Dillon SM, Lee EJ, Kotter CV, et al. An altered intestinal mucosal micro-biome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia. Mucosal Immunol 2014;7:983-94.
23. Vujkovic-Cvijin I, Dunham RM, Iwai S, et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med 2013;5:193ra91.
24. Lozupone CA, Li M, Campbell TB, et al. Alterations in the gut micro-biota associated with HIV-1 infection. Cell Host Microbe 2013;14:329-39.
25. Gonzalez-Hernandez LA, Jave-Suarez LF, Fafutis-Morris M, et al. Syn-biotic therapy decreases microbial translocation and inflammation and improves immunological status in HIV-infected patients: a double-blind randomized controlled pilot trial. Nutr J 2012;11:90.
26. Sandler NG, Zhang X, Bosch RJ, et al. Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. J Infect Dis 2014; pii: jiu305.
27. + T-cell decline and immune activation: a 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (the BITE Study). Clin Infect Dis 2013;57:139-46.
28. Gori A, Rizzardini G, Van't Land B, et al. Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized trial. Mucosal Immunol 2011;4:554-63.
29. Schunter M, Chu H, Hayes TL, et al. Randomized pilot trial of a syn-biotic dietary supplement in chronic HIV-1 infection. BMC Complement Altern Med 2012;12:84.
30. Lim A, Amini A, D'Orsogna LJ, et al. Antibody and B-cell responses may control circulating lipopolysaccharide in patients with HIV infection. AIDS 2011;25:1379-83.
31. Rosette C, Buendia-Laysa F Jr, Patkar S, et al. Anti-inflammatory and immunomodulatory activities of rifamycin SV. Int J Antimicrob Agents 2013;42:182-6.
32. Abad-Fernandez M, Vallejo A, Hernandez-Novoa B, et al. Correlation between different methods to measure microbial translocation and its association with immune activation in long-term suppressed HIV-1-infected individuals. J Acquir Immune Defic Syndr 2013;64:149-53.
33. Kalambokis GN, Mouzaki A, Rodi M, Tsianos EV. Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia. Liver Int 2012;32:467-75.
34. Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis 2014;210:1248-59.
35. Hunt PW, Sinclair E, Rodriguez B, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis 2014;210:1228-38.